BrianThomasHillMD

PubMed

• BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cel...
  Robert Stuver, Agrima Mian, Samantha Brown, Sean Devlin, Paolo F Caimi, Stephanie Chinapen, Parastoo Dahi, Robert Dean, Zachary D Epstein-Peterson, Brian Hill, Steven ...> ;American Journal of Hematology. 2024 Mar 25
• Lenalidomide, rituximab (R), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
  Chen, Y., Cooper, B., Hill, B., Jagadeesh, D., Dean, R., Koc, O., Boughan, K., Pohlman, B., Caimi, P., Smith, M.> ;Leukemia & Lymphoma. 2024 Mar 8
• 3 citations
  Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
  Michael D Jain, Miriam T Jacobs, Feng Gao, Loretta J Nastoupil, Jay Y Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwo...> ;Blood Advances. 2024 Feb 27
• Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
  Hill, B., Ma, S., Zent, C., Baran, A., Wallace, D., Advani, A., Winter, A., Winter, J., Gordan, L., Karmali, R., Liesveld, J., Mulford, D., Rowland, C., Bui, A., Sport...> ;Blood Advances. 2024 Jan 23
• Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
  Colleen A Ramsower, Allison Rosenthal, Ryan S Robetorye, Raphael Mwangi, Matthew Maurer, Diego Villa, Tim McDonnell, Andrew Feldman, Jonathon B Cohen, Thomas Habermann...> ;British Journal of Haematology. 2024 Jan 1
• Impact of active surveillance at time of diagnosis on overall survival in nodular lymphocyte-predominant Hodgkin lymphoma: A National Cancer Database study.
  Victoria M Rogness, Wei Wei, Matthew Cortese, Brian T Hill> ;Leukemia Research. 2023 Nov 1
• The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
  Gabriel F P Aleixo, Wei Wei, Po-Hao Chen, Namita S Gandhi, Faiz Anwer, Robert Dean, Betty K Hamilton, Brian T Hill, Deepa Jagadeesh, Jack Khouri, Brad Pohlman, Ronald ...> ;Bone Marrow Transplantation. 2023 Dec 1
• 1 citations
  Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy.
  Akansha Jalota, Courtney E Hershberger, Manishkumar S Patel, Agrima Mian, Aiman Faruqi, Gholamreza Khademi, Daniel M Rotroff, Brian T Hill, Neetu Gupta> ;Blood Advances. 2023 Sep 12
• 5 citations
  Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
  Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Rachel Treitman, Manali K Kamdar, Bradley M Haverkos, James Godfrey, Melissa A Babcook, Timothy J V...> ;Blood Advances. 2023 Aug 22
• 1 citations
  A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
  Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko, Jason T Romancik, Manali Kamdar, I Brian Greenwell, Brian T Hess, Krista M Isaac, Craig A Portell, Alex Mejia Garcia...> ;Blood Advances. 2023 Jul 11
• Rush Hour Update: Roadblocks to CARs on the Expressway.
  Craig S Sauter, Brian T Hill> ;Transplantation and Cellular Therapy. 2023 Jul 1
• Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
  Danielle S Wallace, Chris Rowland, Brian T Hill, Andrea M Baran, Carla Casulo, Patrick M Reagan, Allison Winter, Reem Karmali, Jane N Winter, Leo I Gordon, Andrew Bui,...> ;Leukemia & Lymphoma. 2023 Sep 1
• A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies.
  Rahul Mishra, Danai Dima, Sumukh A Kumar, Agrima Mian, Alankrita Taneja, Rahul Karna, Paolo F Caimi, Brian T Hill, Robert Dean, Deepa Jagadeesh> ;Hematological Oncology. 2023 Dec 1
• Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP.
  Meredith M Nichols, Sarah L Ondrejka, Sujata Patil, Lisa Durkin, Brian T Hill, Eric D Hsi> ;Leukemia & Lymphoma. 2023 May 24
• 50 citations
  Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
  Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abh...> ;Blood. 2023 May 11
• 1 citations
  Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.
  Agrima Mian, Wei Wei, Betty K Hamilton, Allison M Winter, Jack Khouri, Brad Pohlman, Aaron T Gerds, Deepa Jagadeesh, Faiz Anwer, Matt Kalaycio, Robert M Dean, Ronald S...> ;Bone Marrow Transplantation. 2023 May 1
• 36 citations
  Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
  Yucai Wang, Preetesh Jain, Frederick L Locke, Matthew J Maurer, Matthew J Frank, Javier L Munoz, Saurabh Dahiya, Amer M Beitinjaneh, Miriam T Jacobs, Joseph P Mcguirk,...> ;Journal of Clinical Oncology. 2023 May 10
• 7 citations
  Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
  Brian T Hess, Anshu Giri, Yeonhee Park, Krina K Patel, Brian K Link, Grzegorz S Nowakowski, Seth M Maliske, Sonia Fortin, Julio C Chavez, Hayder Saeed, Brian T Hill, A...> ;American Journal of Hematology. 2023 Feb 1
• 3 citations
  A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
  Matthew J Cortese, Wei Wei, Sebastian Cerdeña, Marcus P Watkins, Marissa Olson, Gray Jodon, Jeff Kaiser, Bradley Haverkos, Mitchell E Hughes, Esin Namoglu, Natalie S G...> ;Leukemia & Lymphoma. 2023 Jan 1
• 1 citations
  Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP.
  Brian T Hill, Brad Kahl> ;Expert Review of Hematology. 2022 Sep 1
• 2 citations
  Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies.
  Agrima Mian, Narendra Bhattarai, Michael Sheu, Sarah L Ondrejka, Paolo F Caimi, Brian T Hill> ;British Journal of Haematology. 2022 Sep 1
• 3 citations
  The safety of Bruton's tyrosine kinase inhibitors in B-cell malignancies: A systematic review.
  Michael Arustamyan, Pavel Kibrik, Dilara Hatipoglu, Brandon Bungo, Amgad Mentias, Brian T Hill, Rohit Moudgil> ;European Journal of Haematology. 2022 Dec 1
• 4 citations
  Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective.
  Scott R Goldsmith, Armin Ghobadi, John F Dipersio, Brian Hill, Mayzar Shadman, Tania Jain> ;Transplantation and Cellular Therapy. 2022 Nov 1
• 1 citations
  Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Anal...
  Michael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, Joost S P Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine T...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Jul 1
• 5 citations
  Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study.
  Firas Baidoun, Muhamad Alhaj Moustafa, Han W Tun, Brian T Hill> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Jul 1
• Join now to see all

Journal Articles

• Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation  
  Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
• Flow Cytometric Analysis of Cerebrospinal Fluid is Low Diagnostic Yield in Samples Without Atypical Morphology or Prior History of Hematologic Malignancy  
  Collie AMB, Hill BT, Stevens GHJ, Fenner K, Gazdick E, His ED, Am J. Clin. Path., 1/1/2014
•  
  Hamilton BK, Rybicki L, Dabney J, McLellan L, Haddad H, Foster L, Abounader D, Kalaycio M, Sobecks R, Dean R, Duong H, Hill BT, Bolwell BJ, Copelan EA, Bone Marrow Transplant, 1/1/2014
• Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor alloge...  
  Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, Hanna R, Sobecks R, Duong H, Hill BT, Copelan E, Bolwell B, Kalaycio M, Am J Hematol, 1/1/2014
• Targeting mTORC1-mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells  
  Sharma A, Janocha AJ, Hill BT, Smith MR, Erzurum SC, Almasan A, Mol Cancer Res, 1/1/2014
• Aggressive B-Cell Lymphomas With Translocations Involving BCL6 and MYC Have Distinct Clinical-Pathologic Characteristics  
  Turakhia SK, Hill BT, Dufresne SD, Nakashima MO, Cotta CV, Am J Clin Pathol, 1/1/2014
• Simultaneous Presentation of IgG4-Related Sclerosing Disease and B-cell Marginal Zone Lymphoma Successfully Treated with Chemoimmunotherapy  
  Bumma N, Cotta C, and Hill BT, Clinical Case Reports, 1/1/2014
• The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis th...  
  Bodo, J, Zhao,X, Sharma, A, Hill, BT, Portell, CA, Lannutti,BJ, Almasan, A and. His, ED, Br J Haematol, 1/1/2013
• Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL)  
  Hill BT, Caimi P, Kindwall-Keller T, Habecker B, Kalaycio M, Br J Haematol, 1/1/2013
• Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hema...  
  Hamilton BK, Bolwell B, Kalaycio M, Rybicki L, Hanna R, Sobecks R, Pohlman B, Andresen S, Dean R, Duong H, Hill, BT, Copelan E, Bone Marrow Transplant, 1/1/2013
• Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Review of the Management of Transplant-Eligible Patients  
  Lukenbill J and Hill BT, Leuk Lymphoma, 1/9/2012
• The Non-Relapse Mortality Rate for Patients with Diffuse Large B-Cell Lymphoma is Greater than Relapse Mortality Eight Years after Autologous Stem Cell Transplantation...  
  Hill, BT., Rybicki, LR., Bolwell, BJ., Smith, S., Dean, R. Kalaycio, M., Pohlman, B., Tench, S., Sobecks, R., Andresen, S., Copelan, E. Sweetenham, J, Br J Haematol, 1/1/2011
• Nonmyeloablative Second Transplants are Associated with Superior Survival and Lower Non-Relapse Mortality than Myeloablative Second Transplants  
  Hill, BT., Bolwell, BJ., Rybicki, L., Dean, R., Kalaycio, M., Pohlman, B., Tench, S., Sobecks, R., Andresen, S., and Copelan, E, Biol Blood Marrow Transplant, 1/1/2010
• Acute Myeloid Leukemia  
  Hill, BT., and Sekeres, MA, Hospital Physician, 1/1/2008
• Human N-Myristoyltransferases form stable complexes with lentiviral Nef and other viral and cellular substrate proteins  
  Hill, BT. and Skowronski, J, J. Virol., 1/1/2005
• HIV-1 Nef binds the DOCK2–ELMO1 complex to activate Rac and inhibit lymphocyte chemotaxis  
  Janardhan, AJ., Swigut, T., Hill, BT., Myers, MP. and Skowronski, J, PLOS, 1/1/2004
• Join now to see all

Books/Book Chapters

• Clinical Ophthalmic Oncology 
  Chapter: Etiology of Cancer 
  Hill, BTEditors: Singh, AD and Damato, B.Springer-Verlag, Berlin & Heidelberg, GermanyEdition 2nd,2014

Abstracts/Posters

• Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase I Trial of Bortezomib and Everolimus in Relapsed/Refractory Non-Hodgkin Lymphoma
  Hill, BT, Smith, MR, Mears, J, Healy, A, Shelley, M, Wyckhouse, J, Kakish, J, Jagadeesh, D, Dean, RM Pohlman,B, Smith, SD, ASH, 1/1/2014
• Bulky Disease Does Not Adversely Affect Overall Survival in Early Stage Hodgkin Lymphoma: Role of Interim PET and Possible Omission of Radiotherapy in Select Patients
  Pophali, PA, Rybicki, L, Fenner, KB, Jagadeesh, J, Dean, RM, Pohlman, B, Smith, MR, Hill, BT, ASH, 1/1/2014
• Comparison of Burkitt Lymphoma (BL) and B-cell Lymphoma, Unclassifiable with Features Intermediate Between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma (BCL-U) P...
  Bumma, N, Caimi, P, Rybicki, L, Jagadeesh, D, Dean RM, Pohlman, B, Smith MR, Hill BT, ASH, 1/1/2014
• Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Bendamustine vs Bendamustine Alone in Patients with Relapsed Chronic Lymph...
  Robak, T, Hellman, A, Kloczko, J, Loscertales, J, Lech-Maranda, E , Pagel, JM, Mato, A, Byrd,JC, Awan, FT, Hebart, H, Garcia-Marco, JA Hill, BT, Hallek, M, Stromatt,..., ASH, 1/1/2014
• Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML)
  Wieduwilt, MJ, Cerny, J, Akard, L, Ustun, C, Ravandi, F, Rossetti, JM, Hill, BT, Brown, J , Kellerman, L, Van Syoc, R, Reed, W. Andreadis. C, ASH, 1/1/2014
• Join now to see all

Lectures

• Maintenance After Frontline Therapy in Follicular Lymphoma? An Appropriate Management Plan for... 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• ASH Review 
  Cleveland, OH - 1/1/2015
• Chronic Lymphocytic Leukemia (CLL) 
  Garfield Heights, OH - 1/1/2014
• Non-Hodgkin Lymphoma 
  Lakewood, OH - 1/1/2013
• Update on Hodgkin Lymphoma 
  Cleveland, OH - 1/1/2012
• An Update in the Management of Follicular Lymphoma 
  Nashville, TN - 1/1/2011
• Chronic Leukemia 
  Cleveland, OH - 1/1/2011
• Join now to see all